[Pterygium. Etiology, clinical aspects and novel adjuvant therapies].
Pterygium is a common UV-induced degeneration of the limbal conjunctiva. Indications for surgery include loss of visual acuity, increasing astigmatism, impending invasion of the optical axis and ocular surface discomfort. Measures to reduce the risk of recurrence include 1. an optimal surgical strategy (intra-operative use of antimetabolites and free conjunctival graft), 2. postoperative topical therapy with steroids and lubricants free of preservatives and 3. long-term UV protection. Novel anti-angiogenic treatment approaches for prevention of recurrence of pterygium are discussed.
Heindl
L M
LM
Augenklinik mit Poliklinik, Universität Erlangen-Nürnberg, Erlangen.
Cursiefen
C
C
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000477:Alkylating Agents / Q000008:administration & dosage; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003228:Conjunctiva / Q000473:pathology / Q000528:radiation effects / Q000637:transplantation; D003937:Diagnosis, Differential; D005123:Eye / Q000528:radiation effects*; D005135:Eye Protective Devices; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D011625:Pterygium / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D011832:Radiation Injuries / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D055502:Secondary Prevention; D014466:Ultraviolet Rays / Q000009:adverse effects*
D000305:Adrenal Cortex Hormones; D000477:Alkylating Agents; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016685:Mitomycin
Curr Opin Ophthalmol. 2002 Aug;13(4):204-12
12165701
Ophthalmologe. 1993 Dec;90(6):688-90
8124034
Am J Ophthalmol. 2005 Mar;139(3):536-7
15767067
Ocul Surf. 2008 Jan;6(1):24-43
18264653
Arch Ophthalmol. 2009 Jan;127(1):31-2
19139334
Am J Ophthalmol. 1998 Nov;126(5):717-9
9822237
Ophthalmology. 1992 Nov;99(11):1647-54
1454338
Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):281-4
17934753
Cornea. 2008 May;27(4):406-10
18434842
Strahlenther Onkol. 2009 Dec;185(12):808-14
20013090
Ophthalmologe. 2009 May;106(5):397-8
19396448
Cornea. 2008 May;27(4):476-9
18434853
Ophthalmology. 2009 Sep;116(9):1630-7
19643487
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4653-9
19458331
Curr Opin Ophthalmol. 2007 Jul;18(4):308-13
17568207
Prog Retin Eye Res. 2004 Mar;23(2):195-228
15094131
Cornea. 2009 Jan;28(1):103-4
19092418
Ophthalmology. 2005 Jun;112(6):1023-30
15885787
Br J Ophthalmol. 1984 May;68(5):343-6
6712914
Ophthalmologe. 2009 May;106(5):399-406
19396447
Curr Eye Res. 2008 Jan;33(1):23-8
18214740
Ophthalmology. 2008 Jun;115(6):e33-8
18439681
Surv Ophthalmol. 2003 Mar-Apr;48(2):145-80
12686302
Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):239-44
19485286
Ophthalmologe. 2001 Sep;98(9):801-10
11594219
Invest Ophthalmol Vis Sci. 2009 May;50(5):2095-102
19151400
Cornea. 2009 Feb;28(2):166-9
19158559
Ophthalmologe. 2009 May;106(5):413-9
19418056